验证数据展示
经过测试的应用
| Positive WB detected in | Jurkat cells, NIH/3T3 cells |
| Positive IP detected in | Jurkat cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
发表文章中的应用
| WB | See 4 publications below |
产品信息
15651-1-AP targets GINS3 in WB, IP, ELISA applications and shows reactivity with human, mouse samples.
| 经测试应用 | WB, IP, ELISA Application Description |
| 文献引用应用 | WB |
| 经测试反应性 | human, mouse |
| 文献引用反应性 | human, mouse |
| 免疫原 | GINS3 fusion protein Ag8247 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Polyclonal |
| 产品类型 | Antibody |
| 全称 | GINS complex subunit 3 (Psf3 homolog) |
| 别名 | GINS complex subunit 3, GINS3, PSF3 |
| 计算分子量 | 25 kDa |
| 观测分子量 | 24 kDa |
| GenBank蛋白编号 | BC005879 |
| 基因名称 | GINS3 |
| Gene ID (NCBI) | 64785 |
| RRID | AB_2247477 |
| 偶联类型 | Unconjugated |
| 形式 | Liquid |
| 纯化方式 | Antigen affinity purification |
| UNIPROT ID | Q9BRX5 |
| 储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| 储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for GINS3 antibody 15651-1-AP | Download protocol |
| IP protocol for GINS3 antibody 15651-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Mol Cell Polε Instability Drives Replication Stress, Abnormal Development, and Tumorigenesis. | ||
J Clin Invest Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. | ||
JCI Insight Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia | ||
Cell Rep Loss of POLE3-POLE4 unleashes replicative gap accumulation upon treatment with PARP inhibitors |
